Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Athira Pharma, Inc. - Common Stock
(NQ:
ATHA
)
4.350
-0.170 (-3.76%)
Streaming Delayed Price
Updated: 12:59 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Athira Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Reverse Stock Split
September 11, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
August 14, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira (ATHA) Q2 Loss Narrows 74%
↗
August 07, 2025
Via
The Motley Fool
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical...
From
Athira Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
July 16, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 09, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 05, 2025
Via
Benzinga
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
May 13, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
May 09, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
February 27, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
December 06, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
November 07, 2024
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
November 01, 2024
Via
Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
↗
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 31, 2024
Via
Benzinga
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
October 22, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
↗
September 19, 2024
Via
Benzinga
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
September 17, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
↗
September 04, 2024
Via
Benzinga
US Stocks Mixed; Trade Gap Widens In July
↗
September 04, 2024
Via
Benzinga
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
↗
September 04, 2024
Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's treatment fosgonimeton, with data showing directional improvements but no...
Via
Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
↗
September 04, 2024
Via
Benzinga
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
September 03, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
↗
August 01, 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
August 01, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
July 31, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
July 09, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
